Advertisement
Canada markets close in 2 hours 36 minutes
  • S&P/TSX

    21,837.94
    -35.78 (-0.16%)
     
  • S&P 500

    5,026.85
    -44.78 (-0.88%)
     
  • DOW

    37,981.44
    -479.48 (-1.25%)
     
  • CAD/USD

    0.7312
    +0.0014 (+0.20%)
     
  • CRUDE OIL

    82.55
    -0.26 (-0.31%)
     
  • Bitcoin CAD

    88,213.05
    -500.59 (-0.56%)
     
  • CMC Crypto 200

    1,396.35
    +13.78 (+1.00%)
     
  • GOLD FUTURES

    2,339.60
    +1.20 (+0.05%)
     
  • RUSSELL 2000

    1,975.06
    -20.36 (-1.02%)
     
  • 10-Yr Bond

    4.7000
    +0.0480 (+1.03%)
     
  • NASDAQ

    15,522.15
    -190.60 (-1.21%)
     
  • VOLATILITY

    16.35
    +0.38 (+2.38%)
     
  • FTSE

    8,078.86
    +38.48 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6808
    -0.0011 (-0.16%)
     

Here Are the Key Products in Sage’s GABA Receptor Portfolio

Here Are the Key Products in Sage’s GABA Receptor Portfolio

As discussed earlier, Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders through two different programs: GABA receptor systems and NMDA receptor systems.